Stocktoria
AbCellera Biologics Inc. ABCL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-11
AbCellera Biologics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% |
| Net margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% |
| FCF margin | -231.7% | -648.4% | -317.7% | 42.6% | 49.6% |
| Return on assets | -10.8% | -12.0% | -9.8% | 10.3% | 11.6% |
| Return on equity | -15.1% | -15.4% | -12.7% | 12.9% | 15.0% |
| Current ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 |
| Revenue growth | 160.6% | -24.2% | -92.2% | 29.4% | 60.9% |
Source: SEC EDGAR filings · CIK 0001703057 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.